文献速递急性肾损伤肾血管病与高血压

肾血管疾病损害人间充质干细胞线粒体功能并削弱其肾脏修复能力

Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells.
PubMed 文献 · J Am Soc Nephrol · 2024-07-16

该研究从肾血管疾病患者和健康志愿者腹部皮下脂肪中提取间充质干细胞(MSC),注入肾动脉狭窄或假手术小鼠,发现患者MSC不能改善血压、血肌酐及狭窄肾灌注氧合,也不能减轻毛细血管丢失、小管损伤和纤维化。测序显示患者MSC线粒体基因下调、miR-378h上调,抑制miR-378h可改善其线粒体结构和修复功能。

要点

  • 肾血管疾病患者自体MSC修复缺血肾脏的能力受损。
  • miR-378h上调靶向线粒体基因是MSC功能受损的可能机制。
  • 抑制miR-378h可改善患者MSC的线粒体结构和修复功能。

核心结论

  • 肾血管疾病损害人MSC的修复能力,可能与miR-378h失调靶向线粒体基因有关。

研究设计与样本

  • 从肾血管疾病患者和健康志愿者腹部皮下脂肪提取MSC(每组n=3),注入肾动脉狭窄或假手术小鼠(每组n=6)。
  • 对MSC进行mRNA/miRNA测序,并在体外和额外肾动脉狭窄小鼠中评估miR-378h模拟物(n=5)或抑制剂(n=4)预处理后的效果。

主要发现

  • 健康志愿者MSC(而非肾血管疾病MSC)降低血压、改善血肌酐及狭窄肾皮质灌注和氧合,并减轻管周毛细血管丢失、小管损伤和纤维化。
  • 肾血管疾病MSC中上调基因主要涉及转录和细胞增殖,下调基因主要编码线粒体蛋白。
  • 上调miRNA(包括miR-378h)主要靶向核编码线粒体基因,下调miRNA主要靶向转录和细胞增殖基因。
  • MSC增殖无差异,但抑制miR-378h后其线粒体结构和体内外修复功能均改善。

临床怎么用

  • 肾血管疾病患者自体MSC修复能力可能受损,临床转化需考虑疾病对细胞功能的影响。
  • miR-378h抑制可能作为改善肾血管疾病患者MSC疗效的潜在策略。

局限性

  • MSC供者样本量小(每组n=3),动物实验每组样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Renovascular disease impairs the capacity of human adipose tissue–derived mesenchymal stem/stromal cells to repair ischemic murine kidneys. miR-378h modulated the capacity of renovascular disease adipose tissue–derived mesenchymal stem/stromal cells to repair ischemic kidneys in vivo. BACKGROUND: Renovascular disease leads to renal ischemia, hypertension, and eventual kidney failure. Autologous transplantation of adipose tissue–derived mesenchymal stem/stromal cells (MSCs) improves perfusion and oxygenation in stenotic human kidneys, but associated atherosclerosis and hypertension might blunt their effectiveness. We hypothesized that renovascular disease alters the human MSC transcriptome and impairs their reparative potency. METHODS: MSCs were harvested from subcutaneous abdominal fat of patients with renovascular disease and healthy volunteers (n=3 each), characterized and subsequently injected (5×105/200 μl) into mice 2 weeks after renal artery stenosis or sham surgery (n=6/group). Two weeks later, mice underwent imaging and tissue studies. MSCs from healthy volunteers and in those with renovascular disease were also characterized by mRNA/microRNA (miRNA) sequencing. Based on these, MSC proliferation and mitochondrial damage were assessed in vitro before and after miRNA modulation and in vivo in additional renal artery stenosis mice administered with MSCs from renovascular disease pretreated with miR-378h mimic (n=5) or inhibitor (n=4). RESULTS: MSCs engrafted in stenotic mouse kidneys. Healthy volunteer MSCs (but not renovascular disease MSCs) decreased BP, improved serum creatinine levels and stenotic-kidney cortical perfusion and oxygenation, and attenuated peritubular capillary loss, tubular injury, and fibrosis. Genes upregulated in renovascular disease MSCs versus healthy volunteer MSCs were mostly implicated in transcription and cell proliferation, whereas those downregulated encoded mainly mitochondrial proteins. Upregulated miRNAs, including miR-378h, primarily target nuclear-encoded mitochondrial genes, whereas downregulated miRNAs mainly target genes implicated in transcription and cell proliferation. MSC proliferation was similar, but their mitochondrial structure and reparative function both in vivo and in vitro improved after miR-378h inhibition. CONCLUSIONS: Renovascular disease impaired the reparative capacity of human MSCs, possibly by dysregulating miR-378h that targets mitochondrial genes. PODCAST: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/JASN/2024_08_21_ASN0000000000000440.mp3

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Eirin A, Siddiqi S, Hughes AG, et al. Renovascular Disease and Mitochondrial Dysfunction in Human Mesenchymal Stem Cells. J Am Soc Nephrol. 2024. PMID: 39012704. doi:10.1681/ASN.0000000000000440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。